// App-Quantinova.ai

944 : Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial

Researchers

Presenter

  • Maria Teresa Petrucci

Principal Investigators

  • Robin Foa

  • John V. Catalano

  • Martin Kropff

  • Zhinuan Yu

  • Lindsay Herbein

  • Christian J. Jacques

  • Antonio Palumbo

Medical Centers

  • University Hospital of Muenster, Muenster, Germany

  • Frankston Hospital and Department of Clinical Haematology, Frankston, Australia

  • University of Torino, AOU S.Giovanni Battista, Division of Hematology, Torino, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Locations

  • Germany

  • Italy

  • Greece

  • Australia

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Peripheral neuropathy

  • Deep vein thrombosis

  • Neutropenia

  • Venous thrombosis

  • Anemia

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

  • Prednisone

  • Melphalan

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved